4-chloro-5-(trifluoromethaneyl)-2H-pyrazole-3-carboxylic acid | 934758-95-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-chloro-5-(trifluoromethaneyl)-2H-pyrazole-3-carboxylic acid
• 英文别名: 4-chloro-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid；4-chloro-5-(trifluoromethyl)-2H-pyrazole-3-carboxylic acid；4-chloro-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid
• CAS: 934758-95-9
• 化学式: C₅H₂ClF₃N₂O₂
• 分子量: 214.531
• InChiKey: SEBYOZQTMJZLAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-氯-3-三氟甲基-5-甲基吡唑 在 potassium permanganate 作用下， 以 水 、 叔丁醇 为溶剂， 生成 4-chloro-5-(trifluoromethaneyl)-2H-pyrazole-3-carboxylic acid
  参考文献：
  名称：

  3-Substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1

  摘要：

  Investigation of 1N-substituted pyrazole-3-carboxanilides as 15-lipoxygenase-1 (15-LOX-1) inhibitors demonstrated that the 1N-substituent was not essential for activity or selectivity. Additional halogen substituents on the pyrazole ring, however, increased activity. Further development led to triazole-4-carboxanilides and 2-(3-pyrazolyl) benzoxazoles, which are potent and selective 15-LOX-1 inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.05.004

文献信息

• [EN] SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS<br/>[FR] DÉRIVÉS D'AZÉTIDINE SUBSTITUÉS EN TANT QUE LIGANDS DE TAAR
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016030310A1

  公开（公告）日：2016-03-03

  The present invention relates to a compound of formula I wherein R1 is hydrogen, methoxy or fluoro; R2/R2' are independently from each other hydrogen, methoxy or fluoro; R3/R4 are independently from each other hydrogen or halogen; R is hydrogen or fluoro; L1 is -CH2-, -NR'-, -0-, -S-, CF2- or CH=; R' is hydrogen or lower alkyl; L2 is a bond, -C(0)NH-, -NH-, -CH2NHC(O)-, -NHC(O)- or -NHC(0)NH-; R is hydrogen, halogen, lower alkoxy, cyano or is phenyl optionally substituted by one or more substituents, selected from halogen, lower alkyl substituted by halogen or lower alkoxy, or is a five or six membered heteroaryl, selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or pyrazolyl, which heteroaryls are optionally substituted by one or more substituents, selected from halogen, lower alkyl, lower alkoxy, cyano, cycloalkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or by phenyl substituted by halogen; N is a ring nitrogen atom in position 1 or 2; or to a pharmaceutically suitable acid addition salt thereof. The compounds of formulas I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及一种具有以下式I的化合物，其中R1是氢、甲氧基或氟；R2/R2'分别独立地是氢、甲氧基或氟；R3/R4分别独立地是氢或卤素；R是氢或氟；L1是-CH2-、-NR'-、-O-、-S-、CF2-或CH=；R'是氢或较低的烷基；L2是键、-C(0)NH-、-NH-、-CH2NHC(O)-、-NHC(O)-或-NHC(0)NH-；R是氢、卤素、较低的烷氧基、氰基或是苯环，可以选择性地被一个或多个取代基取代，所述取代基选自卤素、被卤素或较低的烷氧基取代的较低烷基、或是被卤素取代的苯环，或是一个五元或六元杂环芳基，选自吡啶基、嘧啶基、吡嗪基、吡啶嗪基或吡唑基，这些杂环芳基可以选择性地被一个或多个取代基取代，所述取代基选自卤素、较低的烷基、较低的烷氧基、氰基、环烷基、被卤素取代的较低烷基、被卤素取代的较低烷氧基或被卤素取代的苯基；N是1或2位置的环氮原子；或其药学上适宜的酸盐。式I的化合物对痕量胺相关受体(TAARs)具有良好的亲和力，特别是对TAAR1，可用于治疗抑郁症、焦虑症、双相情感障碍、注意缺陷多动障碍(ADHD)、与压力有关的障碍、如精神分裂症、帕金森病等神经疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的治疗。
• HETEROCYCLIC COMPOUNDS AND NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING SAME
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20200399278A1

  公开（公告）日：2020-12-24

  The present invention provides a compound having an excellent control effect on a harmful arthropod. A compound represented by formula (I) [wherein Q represents a group represented by Q1 or a group represented b Q2; Z represents an oxygen atom or a sulfur atom; A 1 represents a nitrogen atom or the like; A 2 represents a CR 4a or the like; A 3 represents a nitrogen atom, a CR 4b , or the like; B 1 represents a CR 1 or the like; B 2 represents a nitrogen atom, a CR 6b , or the like; B 3 represents a nitrogen atom, a CR 6c , or the like; R 1 represents a C1-C6 chain hydrocarbon group having one or more substituent(s) selected from the group consisting of a cyano group and a halogen atom, or the like; R 2 represents a C1-C6 chain hydrocarbon group or the like; R 3 represents a C1-C6 chain hydrocarbon group or the like; R 4a , R 4b , R 6b , and R 6c are identical to or different from each other, and each represent a hydrogen atom or the like; n represents 0, 1, or 2; and q represents 0, 1, 2, or 3] or an N-oxide compound thereof has an excellent control effect on a harmful arthropod.

  本发明提供了一种对有害节肢动物具有优异控制效果的化合物。由式（I）表示的化合物 [其中 Q代表由Q1表示的基团或由Q2表示的基团; Z代表氧原子或硫原子; A 1 代表氮原子或类似物; A 2 代表CR 4a 或类似物; A 3 代表氮原子、CR 4b 或类似物; B 1 代表CR 1 或类似物; B 2 代表氮原子、CR 6b 或类似物; B 3 代表氮原子、CR 6c 或类似物; R 1 代表具有来自氰基团和卤原子等组成的一个或多个取代基的C1-C6链烃基，或类似物; R 2 代表C1-C6链烃基或类似物; R 3 代表C1-C6链烃基或类似物; R 4a 、R 4b 、R 6b 和R 6c 彼此相同或不同，每个代表氢原子或类似物; n代表0、1或2;以及 q代表0、1、2或3] 或其N-氧化物在有害节肢动物上具有优异的控制效果。
• [EN] MORPHOLIN-PYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS MORPHOLINE-PYRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015165835A1

  公开（公告）日：2015-11-05

  The present invention relates to compounds of formula (I) wherein X is CR or N; R is hydrogen, halogen or lower alkyl; L is a bond, -C(O)- or -C(O)NH-; Ar is phenyl or a five or six membered heteroaryl group, containing one or two N atoms; R1 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen or cycloalkyl; n is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及以下式（I）的化合物，其中X为CR或N；R为氢、卤素或较低的烷基；L为键，-C（O）-或-C（O）NH-；Ar为苯基或含有一个或两个N原子的五元或六元杂环芳基；R1为卤素、较低的烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基或环烷基；n为0、1、2或3；或其药学适宜的酸加合物，所有外消旋混合物，所有对应的对映体和/或光学异构体，可用于治疗抑郁症、焦虑症、双相情感障碍、注意缺陷多动障碍（ADHD）、与压力有关的障碍、精神障碍、精神分裂症、神经疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用、代谢障碍、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• Pyrazoles Useful in the Treatment of Inflammation
  申请人：Pelcman Benjamin

  公开号：US20090143455A1

  公开（公告）日：2009-06-04

  There is provided compounds of formula I, wherein R 1 , R 2 , X 1 , X 2 and n have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

  提供了一种公式为I的化合物，其中R1，R2，X1，X2和n在描述中给出了含义，以及其药学上可接受的盐。这些化合物在治疗需要或希望抑制脂氧合酶（例如15-脂氧合酶）活性的疾病中非常有用，特别是在治疗炎症方面。
• Substituted azetidine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US10023559B2

  公开（公告）日：2018-07-17

  The present invention relates to compounds of formula of formula I wherein R, R1. R2, R2′, R3, R4, R5, L1, L2 and N are as described herein, compositions containing compounds of formula I, methods of manufacture of compounds of formula I and methods of treating psychiatric, metabolic, cardiovascular or sleep disorders with compounds of formula I.

  本发明涉及式 I 的化合物，其中 R、R1.R2、R2′、R3、R4、R5、L1、L2和N如本文所述；含有式I化合物的组合物；式I化合物的制造方法；以及用式I化合物治疗精神、代谢、心血管或睡眠障碍的方法。